支气管哮喘治疗现状及进展

支气管哮喘是一种由多种细胞及细胞组分参与的慢性呼吸道炎性疾病,可引起反复发作性喘息、呼吸困难、胸闷或咳嗽等症状,还伴有呼吸道对多种刺激因子的反应性增高,是严重危害人类健康的常见疾病,发病机制复杂。吸入型糖皮质激素(ICS)+长效β2受体激动剂是目前治疗支气管哮喘的一线药物。但有相当一部分难治性哮喘患者,对于此治疗不敏感。随着对哮喘病理生理学及哮喘炎症分型的不断研究,几种新型炎性介质拮抗剂及呼吸道热成形术成为哮喘治疗的研究新热点。

Status and Progress in Treatment of Bronchial Asthma

Bronchial asthma is a chronic inflammatory disease of airways involved with various cells and inflammatory mediators.The typical symptoms of asthma consist of recurrent wheezing,difficulty in breathing,chest tightness,or cough,as well as increased responsiveness of airways to multiple stimuli.It is a common disease severely impairing human health,with complex pathogenesis.At present,inhaled corticosteroid(ICS) plus long-acting beta 2-agonist(LABA) is the first-line treatment of bronchial asthma,but a considerable amount of refractory patients are not sensitive to the treatment.With the ongoing research of asthma pathophysiology and asthma inflammation genotyping,a various inflammatory mediators and bronchial thermoplasty have become the new hotspots of asthma treatment.